Literature DB >> 22120149

Neocortical and hippocampal amyloid-β and tau measures associate with dementia in the oldest-old.

John L Robinson1, Felix Geser, Maria M Corrada, Daniel J Berlau, Steven E Arnold, Virginia M-Y Lee, Claudia H Kawas, John Q Trojanowski.   

Abstract

The emergence of longevity in the modern world has brought a sense of urgency to understanding age-related neurodegenerative diseases such as Alzheimer's disease. Unfortunately, there is a lack of consensus regarding the correlation between the pathological substrates of neurodegeneration and dementia status, particularly in the oldest-old. To better understand the pathological correlates of dementia in the oldest-old, we characterized the topographical spread and severity of amyloid-β, tau, TDP-43 and α-synuclein pathologies in the 90+ Study, a prospective longitudinal population-based study of ageing and dementia. Neuropathological analysis with immunohistochemically labelled sections was carried out blind to clinical diagnosis on the first 108 participants of the 90+ Study who came to autopsy including participants with dementia (n = 66) and without dementia (n = 42). We used quantitative and/or semi-quantitative measures to assess the burden of amyloid-β, tau, TDP-43 and α-synuclein pathologies as well as hippocampal sclerosis. Amyloid-β and tau were the predominant pathologies in the 90+ Study cohort and both amyloid-β area and tau area occupied measures were strongly associated with the presence of dementia, as was Braak staging but semi-quantitative plaque scores were not. Notably, TDP-43 pathology also correlated with dementia, while α-synuclein distribution did not. In addition, hippocampal sclerosis was specific to participants with dementia and correlated with the presence of limbic TDP-43. In contrast to previous reports, we found that tau and amyloid-β continue to be robust pathological correlates of dementia, even in the oldest-old. While individuals with no dementia had limited hippocampal tau and neocortical amyloid-β pathology, dementia associated with an expansion in pathology, including increased neocortical tau and hippocampal amyloid-β plaques, more abundant neocortical amyloid-β deposition and hippocampal sclerosis with its attendant TDP-43 pathology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22120149      PMCID: PMC3235569          DOI: 10.1093/brain/awr308

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  33 in total

1.  Pathological correlates of dementia in a longitudinal, population-based sample of aging.

Authors:  Joshua A Sonnen; Eric B Larson; Paul K Crane; Sebastien Haneuse; Ge Li; Gerald D Schellenberg; Suzanne Craft; James B Leverenz; Thomas J Montine
Journal:  Ann Neurol       Date:  2007-10       Impact factor: 10.422

2.  Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice.

Authors:  Edward B Lee; Lewis Z Leng; Bin Zhang; Linda Kwong; John Q Trojanowski; Ted Abel; Virginia M-Y Lee
Journal:  J Biol Chem       Date:  2005-12-16       Impact factor: 5.157

Review 3.  Morphological substrates of cognitive decline in nonagenarians and centenarians: a new paradigm?

Authors:  Anouk Imhof; Enikö Kövari; Armin von Gunten; Gabriel Gold; Claire-Bénédicte Rivara; François R Herrmann; Patrick R Hof; Constantin Bouras; Panteleimon Giannakopoulos
Journal:  J Neurol Sci       Date:  2007-02-15       Impact factor: 3.181

4.  Dissociation of neuropathology from severity of dementia in late-onset Alzheimer disease.

Authors:  I Prohovnik; D P Perl; K L Davis; L Libow; G Lesser; V Haroutunian
Journal:  Neurology       Date:  2006-01-10       Impact factor: 9.910

5.  Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies.

Authors:  Kunihiro Uryu; Hanae Nakashima-Yasuda; Mark S Forman; Linda K Kwong; Christopher M Clark; Murray Grossman; Bruce L Miller; Hans A Kretzschmar; Virginia M-Y Lee; John Q Trojanowski; Manuela Neumann
Journal:  J Neuropathol Exp Neurol       Date:  2008-06       Impact factor: 3.685

6.  TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease.

Authors:  Catalina Amador-Ortiz; Wen-Lang Lin; Zeshan Ahmed; David Personett; Peter Davies; Ranjan Duara; Neill R Graff-Radford; Michael L Hutton; Dennis W Dickson
Journal:  Ann Neurol       Date:  2007-05       Impact factor: 10.422

Review 7.  The development of amyloid beta protein deposits in the aged brain.

Authors:  Dietmar R Thal; Estibaliz Capetillo-Zarate; Kelly Del Tredici; Heiko Braak
Journal:  Sci Aging Knowledge Environ       Date:  2006-03-08

8.  Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient.

Authors:  James B Leverenz; Ronald Hamilton; Debby W Tsuang; Aimee Schantz; Darcy Vavrek; Eric B Larson; Walter A Kukull; Oscar Lopez; Douglas Galasko; Eliezer Masliah; Jeffrey Kaye; Randall Woltjer; Christopher Clark; John Q Trojanowski; Thomas J Montine
Journal:  Brain Pathol       Date:  2008-01-29       Impact factor: 6.508

Review 9.  Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium.

Authors:  I G McKeith; D W Dickson; J Lowe; M Emre; J T O'Brien; H Feldman; J Cummings; J E Duda; C Lippa; E K Perry; D Aarsland; H Arai; C G Ballard; B Boeve; D J Burn; D Costa; T Del Ser; B Dubois; D Galasko; S Gauthier; C G Goetz; E Gomez-Tortosa; G Halliday; L A Hansen; J Hardy; T Iwatsubo; R N Kalaria; D Kaufer; R A Kenny; A Korczyn; K Kosaka; V M Y Lee; A Lees; I Litvan; E Londos; O L Lopez; S Minoshima; Y Mizuno; J A Molina; E B Mukaetova-Ladinska; F Pasquier; R H Perry; J B Schulz; J Q Trojanowski; M Yamada
Journal:  Neurology       Date:  2005-10-19       Impact factor: 9.910

10.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.

Authors:  Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2006-08-12       Impact factor: 17.088

View more
  56 in total

Review 1.  Patterns of compensation and vulnerability in normal subjects at risk of Alzheimer's disease.

Authors:  Oscar L Lopez; James T Becker; Lewis H Kuller
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

2.  Comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases.

Authors:  Steven E Arnold; Jon B Toledo; Dina H Appleby; Sharon X Xie; Li-San Wang; Young Baek; David A Wolk; Edward B Lee; Bruce L Miller; Virginia M-Y Lee; John Q Trojanowski
Journal:  J Comp Neurol       Date:  2013-12-15       Impact factor: 3.215

3.  Combined treatment with the phenolics (-)-epigallocatechin-3-gallate and ferulic acid improves cognition and reduces Alzheimer-like pathology in mice.

Authors:  Takashi Mori; Naoki Koyama; Jun Tan; Tatsuya Segawa; Masahiro Maeda; Terrence Town
Journal:  J Biol Chem       Date:  2018-12-18       Impact factor: 5.157

4.  Digital pathology and image analysis for robust high-throughput quantitative assessment of Alzheimer disease neuropathologic changes.

Authors:  Janna Hackett Neltner; Erin Lynn Abner; Frederick A Schmitt; Stephanie Kay Denison; Sonya Anderson; Ela Patel; Peter T Nelson
Journal:  J Neuropathol Exp Neurol       Date:  2012-12       Impact factor: 3.685

5.  Microinfarcts are common and strongly related to dementia in the oldest-old: The 90+ study.

Authors:  María M Corrada; Joshua A Sonnen; Ronald C Kim; Claudia H Kawas
Journal:  Alzheimers Dement       Date:  2016-05-28       Impact factor: 21.566

Review 6.  Challenges of multimorbidity of the aging brain: a critical update.

Authors:  Kurt A Jellinger; Johannes Attems
Journal:  J Neural Transm (Vienna)       Date:  2014-08-05       Impact factor: 3.575

7.  Inhibition of protease-activated receptor 1 (PAR1) ameliorates cognitive performance and synaptic plasticity impairments in animal model of Alzheimer's diseases.

Authors:  Daruoosh Zare; Mohammad Amin Rajizadeh; Marzieh Maneshian; Hossein Jonaidi; Vahid Sheibani; Majid Asadi-Shekaari; Manouchehr Yousefi; Khadijeh Esmaeilpour
Journal:  Psychopharmacology (Berl)       Date:  2021-02-23       Impact factor: 4.530

8.  TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia.

Authors:  Bryan D James; Robert S Wilson; Patricia A Boyle; John Q Trojanowski; David A Bennett; Julie A Schneider
Journal:  Brain       Date:  2016-11-01       Impact factor: 13.501

9.  Brain injury biomarkers are not dependent on β-amyloid in normal elderly.

Authors:  David S Knopman; Clifford R Jack; Heather J Wiste; Stephen D Weigand; Prashanthi Vemuri; Val J Lowe; Kejal Kantarci; Jeffrey L Gunter; Matthew L Senjem; Michelle M Mielke; Rosebud O Roberts; Bradley F Boeve; Ronald C Petersen
Journal:  Ann Neurol       Date:  2013-02-19       Impact factor: 10.422

Review 10.  Transgenic models of Alzheimer's disease: better utilization of existing models through viral transgenesis.

Authors:  Thomas L Platt; Valerie L Reeves; M Paul Murphy
Journal:  Biochim Biophys Acta       Date:  2013-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.